Patent · US Active

Compositions and methods relating to anti-IGF-1 receptor antibodies

US8895008B2 · kind B2 · utility

1Cited by
15References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 10, 2013
Grant dateNov 25, 2014
Priority date—
Expiry dateMay 10, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.